CN1338310A - Epitope vaccine of hog cholera virus and its preparing process - Google Patents
Epitope vaccine of hog cholera virus and its preparing process Download PDFInfo
- Publication number
- CN1338310A CN1338310A CN00121292A CN00121292A CN1338310A CN 1338310 A CN1338310 A CN 1338310A CN 00121292 A CN00121292 A CN 00121292A CN 00121292 A CN00121292 A CN 00121292A CN 1338310 A CN1338310 A CN 1338310A
- Authority
- CN
- China
- Prior art keywords
- swine fever
- epitope
- fever virus
- vaccine
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000710777 Classical swine fever virus Species 0.000 title claims abstract description 66
- 229960005486 vaccine Drugs 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims description 5
- 229920001184 polypeptide Polymers 0.000 claims abstract description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 33
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 33
- 230000008878 coupling Effects 0.000 claims abstract description 23
- 238000010168 coupling process Methods 0.000 claims abstract description 23
- 238000005859 coupling reaction Methods 0.000 claims abstract description 23
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 12
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 12
- 230000003472 neutralizing effect Effects 0.000 claims description 27
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 10
- 230000000890 antigenic effect Effects 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000012752 auxiliary agent Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 description 13
- 206010037660 Pyrexia Diseases 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 9
- 230000036039 immunity Effects 0.000 description 4
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 3
- 206010008631 Cholera Diseases 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 238000012109 statistical procedure Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000710778 Pestivirus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- LXWYCLOUQZZDBD-LIYNQYRNSA-N csfv Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LXWYCLOUQZZDBD-LIYNQYRNSA-N 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/187—Hog cholera virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
An epitope vaccine of hog oholera virus contains at least one epitope polypeptide which is coupled to carrier protein or carrier polypeptide to form conjugate and contains at least once repeated monoepitope or polyepitope. The process for preparing said vaccine includes synthesizing said polypeptide, coupling it to carrier to form conjugate, and adding auxiliary agent to obtain said vaccine. Said vaccine can effectively treat the variation of hog cholera virus.
Description
The present invention relates to vaccine with the biotechnology preparation and preparation method thereof, particularly relate to a kind of classical swine fever virus vaccine and preparation method thereof.
Swine fever is that (HCV) the pernicious communicate illness of Yin Faing is in case outburst often brings enormous economic loss at short notice for Classical Swine fever virus, CSFV or Hog Choleravirus by swine fever virus.As far back as the fifties, China has just developed hog cholera lapinised virus vaccine, this vaccine is a kind of of attenuated live vaccine, utilize the live hog Pestivirus behind the attenuation to come the induction of immunity protection, controlled swine fever being very popular and distributing effectively in China, fine because of its safety and preventive effect, many countries also use this vaccine.Enter the later stage seventies, swine fever popular with distribute with chronic infection be feature, and the immuning failure phenomenon generally appears.Fact proved, when the swine fever that the swine fever virus that existing hog cholera lapinised virus vaccine morphs at pre-Radix Stephaniae Tetrandrae causes is popular, exist very big difficulty.The swine fever virus subunit vaccine is a kind of swine Fever Vaccine of developing both at home and abroad at present, and this vaccine is to utilize the virus envelope protein of gene recombinaton to come the induction of immunity protection.Though this vaccine can tackle the variation of swine fever virus to a certain extent, only comprise a hereditary information of virus in the vaccine, when virus morphed, this vaccine promptly can lose effectiveness, and the production cost of this vaccine is still higher at present.
On the other hand, the antigenic region sequence on the swine fever virus envelope protein E 2 (690-866 amino acids residue) be proved can induction of immunity protection, (Vaccine 2000,18:2351 can to protect the infection of pig prevention swine fever virus; Vaccine 1999,17:433; J.Virology 1995,69:6479; Vaccine 2000,18:1374; J.Virology 1993,67:5435).
Simultaneously, the present inventor discovers that the epitope polypeptide of multi-epitope can be induced the neutralizing antibody of high titre, predefined, many neutralizing epitope and variant epitope epitope specificity.
The purpose of this invention is to provide a kind of swine fever virus epiposition vaccine that can do with the swine fever virus variation.
Another object of the present invention provides a kind of method of producing above-mentioned swine fever virus epiposition vaccine.
For achieving the above object, the present invention takes following design: a kind of swine fever virus epiposition vaccine, it comprise at least one be coupled on carrier protein or the carrier polypeptide form coupling matter contain at least once the multiple single epi-position or the epitope polypeptide of multiple multi-epitope at least once, described epi-position is selected from neutralizing epitope and the variant epitope on the swine fever virus envelope protein E 2.
Neutralizing epitope on the described swine fever virus envelope protein E 2 or variant epitope are positioned at the antigenic region on the swine fever virus envelope protein E 2.
More particularly, described antigenic region is the 690-866 amino acids residue on the swine fever virus envelope protein E 2.
Described neutralizing epitope can be selected from:
RRYLASLH
SVTFEL
DTSPVV
KGKYNT
DDFRFG
The variant epitope of described neutralizing epitope can be selected from:
KGALLTS
KKALPTS
KEALPTS
YSHDLQ
YNHDLQ
YSODLQ
YNHNLQ
KGKYNT
KAICVA
KASCVA
KAVCTA
Described vaccine can be to comprise being coupled on carrier protein or the carrier polypeptide in the following polypeptide that forms coupling matter one or several respectively:
CRRYLASLHGRRYLASLHGRRYLASLH
CSVTFELGSVTFELGSVTFELGSVTFEL
CDTSPVVGDTSPVVGDTSPVVGDTSPVV
CKGKYNTGKGKYNTGKGKYNTGKGKYNT
CDDFRFGGDDFRFGGDDFRFGGDDFRFG
In order to make vaccine can induce stronger immunity, also comprise acceptable medicinal adjuvant in the vaccine.
A kind of method for preparing above-mentioned swine fever virus epiposition vaccine consists essentially of following steps:
(1), synthetic at least one contains at least once the epitope polypeptide of the single neutralizing epitope of antigenic region on the multiple swine fever virus envelope protein E 2 or single variant epitope or a plurality of neutralizing epitope or a plurality of variant epitope or a plurality of neutralizing epitope and variant epitope;
(2), above-mentioned epitope polypeptide is coupled to respectively on carrier protein or the carrier polypeptide forms coupling matter;
(3), above-mentioned coupling matter is equipped with acceptable adjuvant and is prepared into the swine fever virus epiposition vaccine.
The polypeptide of described synthetic can be selected from:
CRRYLASLHGRRYLASLHGRRYLASLH
CSVTFELGSVTFELGSVTFELGSVTFEL
CDTSPVVGDTSPVVGDTSPVVGDTSPVV
CKGKYNTGKGKYNTGKGKYNTGKGKYNT
CDDFRFGGDDFRFGGDDFRFGGDDFRFG
It is stronger that the present invention utilizes the neutralizing epitope on the swine fever virus envelope protein E 2 can induce pig to produce, and the time is than the characteristic of long immune protection, at the more characteristics of swine fever virus variation, the utilization multiple vaccines makes pig produce multiple antibody to swine fever virus, that is to say, when one or several epi-position of swine fever virus morphs, the pig of having injected vaccine be enough in addition to tackle this variation swine fever virus corresponding to other antibody of variant epitope not.Vaccine of the present invention has the following advantages: 1, this vaccine is a kind of efficient multiple vaccines that can stimulate the multiple neutralizing antibody of generation, can effectively tackle the variation of virus, and then overcomes existing swine Fever Vaccine preventive effect difference even invalid shortcoming.2, the effective ingredient of this vaccine be coupled on carrier protein or the carrier polypeptide form coupling matter include the neutralizing epitope on the swine fever virus envelope protein E 2 or the epitope polypeptide of variant epitope, these epitope polypeptides do not need the native protein of the pathogen or the pathogen of attenuation or deactivation, the nucleic acid that does not also need gene recombinant protein antigen and pathogen, can directly induce predetermined, a plurality of neutralizing epitopes and variant epitope antigen-specific immune responses, the hereditary material and the activity that do not have swine fever virus, can not produce the side effect that the hereditary material because of swine fever virus brings out, there is not the danger of inactivated vaccine or attenuated vaccine possibility renaturation yet, also can get rid of simultaneously and use swine fever attenuated vaccine (as hog cholera lapinised virus vaccine) boar, induce in sow and the barren sow body generation swine fever attenuated live virus infection and duplicate, thereby overcome swine fever attenuated live viral infection barren sow to the mankind bring potential, unknown at present harm.3, can induce very strong immunne response at specific neutralizing epitope, be the inductive specific neutralizing antibody level of corresponding subunit vaccine 10-20 doubly, be 10-240 mcg/ml serum at the antibody amount of specific neutralizing epitope.4, according to the variation of swine fever virus, can produce the vaccine of its respective type very soon, need not test for a long time, reduce production costs.This technology will produce significant impact to world's preventive medicine research, will make the technology of preparing of classical swine fever virus vaccine produce revolutionary variation, and will bring huge economic benefit and social benefit.
The invention will be further described below in conjunction with non-limiting specific embodiment.
Embodiment 1, preparation are based on the single epi-position-swine fever virus epiposition vaccine of swine fever virus E2 albumen:
1. synthetic contains swine fever virus E2 proteantigen district (690-866 amino acids residue) sequence neutralizing epitope KGKYNT, and repeats 4 times epitope polypeptide:
CKGKYNTGKGKYNTGKGKYNTGKGKYNT
2. utilize MBS (m-maleimidobenzoyl-N-hydroxy succinimide ester) with this epitope polypeptide and carrier protein bovine serum albumin coupling connection;
3. above-mentioned coupling matter is equipped with oily adjuvant and is prepared into the single epi-position-epiposition vaccine of swine fever virus.
Embodiment 2, the preparation based on the swine fever virus of swine fever virus E2 albumen multi-joint-epiposition vaccine:
1. synthetic contains 5 main neutralizing epitopes of swine fever virus E2 proteantigen region sequence respectively, and repeated 5 epitope polypeptides:
CRRYLASLHGRRYLASLHGRRYLASLH
CSVTFELGSVTFELGSVTFELGSVTFEL
CDTSPVVGDTSPVVGDTSPVVGDTSPVV
CKGKYNTGKGKYNTGKGKYNTGKGKYNT
CDDFRFGGDDFRFGGDDFRFGGDDFRFG
2. utilize glutaraldehyde that 5 kinds of epitope polypeptides are joined with carrier protein BSA coupling respectively;
3. above-mentioned coupling matter is equipped with oily adjuvant and mixes, be prepared into swine fever virus multi-joint-epiposition vaccine.Wherein, the variation probability in the portion rate of 5 kinds of coupling matters each site that can draw according to the different year statistical procedures is adjusted.
Embodiment 3, preparation are based on the swine fever virus multiepitope epitope vaccine of swine fever virus E2 albumen:
1. synthetic contains the repetition epitope polypeptide of 2 neutralizing epitopes of swine fever virus E2 proteantigen region sequence:
CRRYLASLHGSVTFELCRRYLASLHGSVTFEL
2. utilize MBS (m-maleimidobenzoyl-N-hydroxy succinimide ester) with this epitope polypeptide and carrier protein chicken ovalbumin coupling connection;
3. above-mentioned coupling matter is equipped with oily adjuvant and is prepared into the swine fever virus multiepitope epitope vaccine.
Embodiment 4, preparation are based on the swine fever virus multi-epitope-multi-joint-epiposition vaccine of swine fever virus E2 albumen:
1. synthetic contains 4 epitope polypeptides of the main neutralizing epitope of the multiple difference of swine fever virus E2 proteantigen region sequence:
CRRYLASLHGSVTFELGRRYLASLHGSVTFEL
CSVTFELGDTSPVVGSVTFELGDTSPVV
CKGKYNTGDDFRFGKGKYNTGDDFRFG
CGDDFRFGSVTFELGDDFRFGSVTFEL
2. utilize glutaraldehyde that 4 kinds of epitope polypeptides are joined with carrier protein chicken ovalbumin coupling respectively;
3. above-mentioned coupling matter is equipped with oily adjuvant and mixes, be prepared into multi-epitope-multi-joint-swine fever epiposition vaccine.Wherein, the variation probability in the portion rate of 4 kinds of coupling matters each site that can draw according to the different year statistical procedures is adjusted.
Embodiment 5, the preparation based on the swine fever virus resistance of swine fever virus E2 albumen different-multi-joint-epiposition vaccine, step is:
1. synthetic contains 13 epitope polypeptides of the main neutralizing epitope of the multiple difference of swine fever virus E2 proteantigen region sequence and its variant epitope:
CKGALLTSGKGALLTSGKGALLTS
CKKALPTSGKKALPTSGKKALPTS
CKEALPTSGKEALPTSGKEALPTS
CYSHDLQGYSHDLQGYSHDLQGYSHDLQ
CYNHDLQGYNHDLQGYNHDLQGYNHDLQ
CYSQDLQGYSQDLQGYSQDLQGYSQDLQ
CYNHNLQGYNHNLQGYNHNLQGYNHNLQ
CKGKYNTGKGKYNTGKGKYNTGKGKYNT
CKGKYNTGKGKYNTGKGKYNTGKGKYNT
CKGKYNTGKGKYNTGKGKYNTGKGKYNT
CKAICVAGKAICVAGKAICVAGKAICVA
CKASCVAGKASCVAGKASCVAGKASCVA
CKAVCTAGKAVCTAGKAVCTAGKAVCTA
2. utilize MBS (m-maleimidobenzoyl-N-hydroxy succinimide ester) that above-mentioned epitope polypeptide is joined with carrier protein bovine serum albumin coupling respectively;
3. above-mentioned coupling matter is equipped with oily adjuvant and mixes, be prepared into swine fever virus multi-epitope-multi-joint-epiposition vaccine.Wherein, the variation probability in the portion rate of 13 kinds of coupling matters each site that can draw according to the different year statistical procedures is adjusted.
Claims (9)
1, a kind of swine fever virus epiposition vaccine, it comprise at least one be coupled on carrier protein or the carrier polypeptide form coupling matter contain at least once the multiple single epi-position or the epitope polypeptide of multiple multi-epitope at least once, described epi-position is selected from neutralizing epitope and the variant epitope on the swine fever virus envelope protein E 2.
2, swine fever virus epiposition vaccine according to claim 1 is characterized in that: neutralizing epitope on the described swine fever virus envelope protein E 2 and variant epitope are positioned at the antigenic region on the swine fever virus envelope protein E 2.
3, swine fever virus epiposition vaccine according to claim 2 is characterized in that: described antigenic region is the 690-866 amino acids on the swine fever virus envelope protein E 2.
4, according to claim 1 or 2 or 3 described swine fever virus epiposition vaccines, it is characterized in that: described neutralizing epitope is selected from:
RRYLASLH
SVTFEL
DTSPVV
KGKYNT
DDFRFG
Described variant epitope is selected from:
KGALLTS
KKALPTS
KEALPTS
YSHDLQ
YNHDLQ
YSODLQ
YNHNLQ
KGKYNT
KAICVA
KASCVA
KAVCTA
5, swine fever virus epiposition vaccine according to claim 4 is characterized in that: described vaccine comprises one or several in the following polypeptide that is coupled to formation coupling matter on carrier protein or the carrier polypeptide respectively:
CRRYLASLHGRRYLASLHGRRYLASLH
CSVTFELGSVTFELGSVTFELGSVTFEL
CDTSPVVGDTSPVVGDTSPVVGDTSPVV
CKGKYNTGKGKYNTGKGKYNTGKGKYNT
CDDFRFGGDDFRFGGDDFRFGGDDFRFG
6, according to claim 1 or 2 or 3 or 5 described swine fever virus epiposition vaccines, it is characterized in that: also comprise acceptable medicinal adjuvant in the vaccine.
7, swine fever virus epiposition vaccine according to claim 4 is characterized in that: also comprise acceptable medicinal adjuvant in the vaccine.
8, a kind of method for preparing the swine fever virus epiposition vaccine consists essentially of following steps:
(1), synthetic at least one contains at least once the epitope polypeptide of the single neutralizing epitope of antigenic region on the multiple swine fever virus envelope protein E 2 or single variant epitope or a plurality of neutralizing epitope or a plurality of variant epitope or a plurality of neutralizing epitope and variant epitope;
(2), above-mentioned epitope polypeptide is coupled to respectively on carrier protein or the carrier polypeptide forms coupling matter;
(3), above-mentioned coupling matter is equipped with acceptable adjuvant and is prepared into the swine fever virus epiposition vaccine.
9, a kind of method for preparing the swine fever virus epiposition vaccine according to claim 8, it is characterized in that: the polypeptide of described synthetic is selected from:
CRRYLASLHGRRYLASLHGRRYLASLH
CSVTFELGSVTFELGSVTFELGSVTFEL
CDTSPVVGDTSPVVGDTSPVVGDTSPVV
CKGKYNTGKGKYNTGKGKYNTGKGKYNT
CDDFRFGGGDDFRFGGDDFRFGGDDFRFG
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00121292A CN1338310A (en) | 2000-08-10 | 2000-08-10 | Epitope vaccine of hog cholera virus and its preparing process |
| AU2002212073A AU2002212073A1 (en) | 2000-08-10 | 2001-07-20 | A classical swine fever virus epitope vaccine and its producing method |
| PCT/CN2001/001189 WO2002020048A1 (en) | 2000-08-10 | 2001-07-20 | A classical swine fever virus epitope vaccine and its producing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00121292A CN1338310A (en) | 2000-08-10 | 2000-08-10 | Epitope vaccine of hog cholera virus and its preparing process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1338310A true CN1338310A (en) | 2002-03-06 |
Family
ID=4588705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN00121292A Pending CN1338310A (en) | 2000-08-10 | 2000-08-10 | Epitope vaccine of hog cholera virus and its preparing process |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN1338310A (en) |
| AU (1) | AU2002212073A1 (en) |
| WO (1) | WO2002020048A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101152570B (en) * | 2007-10-19 | 2010-11-24 | 清华大学 | Epitope vaccine of hog cholera virus and its preparing process |
| CN101144818B (en) * | 2007-10-19 | 2011-04-27 | 清华大学 | Method for detecting pig plague virus specific antibody and its ELISA reagent kit |
| CN102268079A (en) * | 2011-05-03 | 2011-12-07 | 新乡学院 | (Classical swine fever virus) CSFV E2 protein ligand epitope peptide and application thereof |
| CN106928327A (en) * | 2017-04-01 | 2017-07-07 | 河南科技学院 | CSFV part epitope polypeptide SE242 and its application |
| CN110327462A (en) * | 2019-07-01 | 2019-10-15 | 大连民族大学 | A kind of liposome bacterin and preparation method thereof |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103224477A (en) | 2005-12-22 | 2013-07-31 | 高点制药有限责任公司 | Phenoxy acetic acids as PPAR delta activators |
| CN102965332B (en) * | 2011-11-30 | 2014-06-04 | 普莱柯生物工程股份有限公司 | Swine testicular clone cell line and production method of classical swine fever live vaccine |
| KR102025488B1 (en) * | 2015-05-15 | 2019-09-25 | 레버 제네틱스 컴퍼니 리미티드 | Novel baculovirus vectors and methods of use |
| CN111116720B (en) * | 2020-02-24 | 2022-02-15 | 中牧实业股份有限公司 | Classical swine fever virus recombinant E2 protein and application thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4761470A (en) * | 1985-12-16 | 1988-08-02 | Merck & Co., Inc. | Immunogenic synthetic peptide capable of eliciting herpes simplex virus neutralizing antibody |
| FR2671554A1 (en) * | 1991-01-11 | 1992-07-17 | Clonatec Sa | HEPATITIS B VIRUS-BASED HBC ANTIGEN SYNTHETIC PEPTIDES, THEIR USE IN THE DETECTION OF VIRUS INFECTION AND VACCINATION AGAINST HEPATITIS B. |
| PL184836B1 (en) * | 1994-06-17 | 2002-12-31 | Inst Voor Veehouderij En Dierg | Nucleotidic sequences of pestviral strains, polypeptides encoded by means of such sequences and their application in diagnosis and prevention of pestviral infections |
| ATE206458T1 (en) * | 1994-12-20 | 2001-10-15 | Akzo Nobel Nv | T-CELL-STIMULATING PROTEIN FROM PESTIVIRUS |
| EP0924298A1 (en) * | 1997-12-18 | 1999-06-23 | Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) | Protein expression in baculovirus vector expression systems |
| US7018637B2 (en) * | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
-
2000
- 2000-08-10 CN CN00121292A patent/CN1338310A/en active Pending
-
2001
- 2001-07-20 AU AU2002212073A patent/AU2002212073A1/en not_active Abandoned
- 2001-07-20 WO PCT/CN2001/001189 patent/WO2002020048A1/en active Application Filing
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101152570B (en) * | 2007-10-19 | 2010-11-24 | 清华大学 | Epitope vaccine of hog cholera virus and its preparing process |
| CN101144818B (en) * | 2007-10-19 | 2011-04-27 | 清华大学 | Method for detecting pig plague virus specific antibody and its ELISA reagent kit |
| CN102268079A (en) * | 2011-05-03 | 2011-12-07 | 新乡学院 | (Classical swine fever virus) CSFV E2 protein ligand epitope peptide and application thereof |
| CN102268079B (en) * | 2011-05-03 | 2013-04-03 | 新乡学院 | (Classical swine fever virus) CSFV E2 protein ligand epitope peptide and application thereof |
| CN106928327A (en) * | 2017-04-01 | 2017-07-07 | 河南科技学院 | CSFV part epitope polypeptide SE242 and its application |
| CN106928327B (en) * | 2017-04-01 | 2020-02-04 | 河南科技学院 | Hog cholera virus ligand epitope polypeptide SE242 and application thereof |
| CN110327462A (en) * | 2019-07-01 | 2019-10-15 | 大连民族大学 | A kind of liposome bacterin and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002020048A1 (en) | 2002-03-14 |
| AU2002212073A1 (en) | 2002-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1086589C (en) | Vaccines | |
| CN1091978A (en) | CSF 393000 is as the purposes of vaccine adjuvant | |
| CN1227032C (en) | Vaccines with an LTB adjuvant | |
| CN104262488B (en) | A kind of preparation and application of fusion protein and its vaccine combination | |
| Park et al. | Enhanced immune responses of foot-and-mouth disease vaccine using new oil/gel adjuvant mixtures in pigs and goats | |
| CN1241639C (en) | Vaccine composition against malaria | |
| CN1299288A (en) | Combined vaccine compositions | |
| JP2001526688A (en) | Oligonucleotide adjuvant | |
| CN1665528A (en) | Adjuvanted viral particles | |
| Park et al. | Protection of chicken against very virulent IBDV provided by in ovo priming with DNA vaccine and boosting with killed vaccine and the adjuvant effects of plasmid-encoded chicken interleukin-2 and interferon-γ | |
| CN1338310A (en) | Epitope vaccine of hog cholera virus and its preparing process | |
| Bedekar et al. | Fundamentals of fish vaccination | |
| Bai et al. | Hollow mesoporous silica nanoparticles as delivery vehicle of foot‐and‐mouth disease virus‐like particles induce persistent immune responses in guinea pigs | |
| RU2015113826A (en) | ISOLATION OF VIRUS RELATED TO PARVOVIRUS-2 DOGS, FROM RACON | |
| JP2006521321A (en) | Use of alum and Th1 immune response inducing adjuvants to promote immune responses | |
| CN1338309A (en) | Synthetic peptide vaccine of hog cholera and its preparing process | |
| CN1408349A (en) | Foot-and-mouth disease gene engineering polypeptide vaccine and its preparing method | |
| CN1275649C (en) | Bivalence polypeptide vaccine for resisting A type and O type foot-and-mouth disease virus and its preparation | |
| EP0434749B1 (en) | Pharmaceutical compositions for eliciting an immunostimulant effect | |
| CN1036838C (en) | Live combination vaccine | |
| CN1338307A (en) | Epitope vaccine of influenza virus and its preparing process | |
| Shao et al. | DNA fragment encoding human IL-1β 163–171 peptide enhances the immune responses elicited in mice by DNA vaccine against foot-and-mouth disease | |
| KR20070048140A (en) | Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus | |
| CN1163271C (en) | Synthetic peptide vaccine of influenzand its preparing process | |
| CN111840533B (en) | A-type foot-and-mouth disease virus-like particle antigen, vaccine composition thereof, preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |